CJC1295+GHRP-6 BLEND 2MG/2MG

CJC-1295 is a synthetic agonist of growth hormone-releasing hormone receptor. It binds to the GHRH receptor in the pituitary gland and boosts the physiological pulsatile secretion of GH. On the other hand, GHRP-6 acts on the ghrelin/ growth hormone secretagogue receptor and increases the baseline levels of GH.

These two man-made compounds are likely to give an additive effect when combined. GHRP-2 increases the set levels of GH, making sure the lowest level GH drops to is higher than under normal conditions. While CJC-1295 boosts the GH secretion in a pulsatile manner using the higher baseline levels set by GHRP-2 and produces elevated peaks [1].

Research shows that CJC-1295 and GHRP-6 can promote muscle growth, accelerate recovery and enhance strength performance [2, 3]. And, GHRP-6 has been studied in laboratory settings regarding appetite-related behaviors and sleep-related physiologic processes. Feeding patterns and measures of sleep are frequently assessed in relation to growth hormone activity. In addition, these peptides have been evaluated in experimental models for their effects on cardiovascular-related targets and neuronal signaling events [4,5,6,7]. Research on animal models using these two peptides is likely to show the synergistic effect. At Pinnacle Peptides, the CJC-1295 + GHRP-6 blend for sale is exclusively available for research and experimentation.

1. Ionescu, M. and L.A. Frohman, Pulsatile secretion of growth hormone (GH) persist during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 2006. 91(12): p. 4792-7.
2. Van Hout, M.C. and E. Hearne, Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse, 2016. 51(1): p. 73-84.
3. Mendoza Marí, Y., et al., Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plast Surg Int, 2016. 2016: p. 4361702.
4. Berlanga, J., et al., Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clinical Science, 2007. 112(4): p. 241-250.
5. Xu, X.-B., et al., GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. American Journal of Physiology-Heart and Circulatory Physiology, 2005. 289(4): p. H1643-H1651.
6. Madhavadas, S., B.M. Kutty, and S. Subramanian, Amyloid beta lowering and cognition-enhancing effects of ghrelin receptor analog [D-Lys (3)] GHRP-6 in rat model of obesity. Indian J Biochem Biophys, 2014. 51(4): p. 257-62.
7. Subirós, N., et al., Assessment of dose–effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurological Research, 2016. 38(3): p. 187-195.